come hard part
beat expect investor expect
sequenc hardwar array guidanc look
modestli stronger call mark slow pt
surpris headlin beat top line like bit
ahead investor expect feedback suggest beat
anticip sequenc hardwar proxi demand novaseq
sequenc hardwar result quarter weaker estim
may suggest mute demand survey global sequenc
survey view local found outsid larg send-
lab on-track visibl howev limit novaseq order
shipment figur longer provid high level instrument revenu
trend revenu flat/down vs year ago consist thesi
observ excess capac market upsid array beat
forecast primarili reflect consum genom demand
post holiday season price-cut heavi promot big player
space sustain trend unclear agre
long tail growth growth array servic
unpreced effect beg question larg consum
genom market ultim long level promot
compani space continu given clariti
expect growth categori balanc year sequenc
consum strong though mayb surpris continu ramp
like runway balanc good quarter pt
goe yield
guidanc realli chang impli rais top line
guidanc array beat quarter least
rel model would yield increment growth
also flag revenu come pharma collabor
previous guidanc though dynam size all-in see
minor underli chang guidanc sequenc
consumables/collaborations/array posit clear hardwar
expect track rel prior reiter expect
shipment novaseq year suggest chang modest
consum growth tough model top sustain
array/consum trend hardwar demand specif driver
chang guidanc driver consum revenu key sequenc
life scienc tool diagnost unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
consum growth surg remain level
though easier comp growth surg logic includ stock
novaseq flowcel advanc convert project hiseq/x fleet
transit dynam arguabl unpreced prior launch
either smaller number target new market
estim novaseq pullthrough alreadi reach hiseq
pullthrough declin last quarter expect
continu stock less clear estim novaseq consum
revenu q/q academic/pharma lab survey suggest novaseq
expect drive acceler overal consum spend growth
longer term strong double-digit growth look persist
path stock bit harder guidanc logic call
slow cours year
effect revers pattern comp get tougher back-half
stronger pend pharma array consum stock
clear howev investor absorb growth moder stock price-to-earnings
revis guidanc expect ep growth
next two year appreci deserv premium multipl
rest tool given longer term bull case behind clinic sequenc includ
believ multipl rang justifi given stock
similar eps/fcf outlook yet investor
demand yield ilmn
consum trend strong bit bullish nih
previous call strong nih disburs trend flag
moder dive deeper nih spend given hardwar result
appear consum trend hardwar
may see durabl benefit recoveri nih disburs
last month ilmn sequenc consum growth surg
encouragingli remain level remain tailwind
consumables-heavi player given lighter hardwar mix
suggest trend earli mayb less support agil
margin may set floor stock perhap biggest surpris vs model
beyond top-lin beat behind array servic margin gross
margin beat mse/consensu opex saw even greater
delta note opex came lower expect due
time headcount addit invest exhibit said
suggest opex revenu flat slightli y/i
intend ramp growth-ori invest impli opex step
q/q revenu revenu remain elev
suggest new ep guidanc may still
conserv updat model reflect fewer shipment
driven mostli weaker faster pull-through declin legaci hiseq
given step-down saw higher pull-through
off-set sequenc consum estim goe net higher
faster array servic growth behind sustain dtc custom momentum
expect step-up opex result rais
revenu estim ep higher see chang
exhibit rais pt base yield estim
growth unlik satisfi multipl
growth unlik satisfi
multipl
cancer prenat becom standard care next
month market penetr follow adopt curv like new drug
new diagnost test regulatori approv guidelin inclus drive
clinician adopt new approach cancer prenat care guidelin
revis support cancer prenat test uptak
reimburs clinic applic improv test standard
guidelin revis support medicar code refin research
market growth improv success penetr smaller lab
novaseq launch support near-term double-digit top-line growth
consum slow inflect oncolog remain event
uptak clinic applic remain concentr academ
commun hospit refin eas use new
softwar sampl prepar system on-going regulatori approv
guidelin inclus anticip emerg year research
market growth remain weak competit emerg medium
growth slow ahead broader clinic adopt placement novaseq
hiseq system slower expect demand prove
limit outsid major genom center uptak clinic applic
remain concentr academ commun center
refin eas use new softwar sampl prepar system
on-going reimburs clinic applic remain limit
privat pay group despit progress medicar code rate regulatori
approv guidelin inclus cancer prenat applic
uncertain call long-term outcom data becom pronounc
research market remain roughli flat govern budget pressur
interest competit platform grow threaten domin
domin player next-
gener sequenc
expect broader applic
diagnost aid cancer prenat
applic longer term expect
traction measur ahead updat
clinic guidelin widespread
reimburs emerg
market like remain subdu due
physician group support clinic
guidelin evolut broader adopt
clinic set look public
expert consortia clinic trial
fda insur support includ
regulatori approv standard test
posit reimburs polici
expand interest research tailor
innov sampl prepar
softwar support adopt user
smaller clinic hospit
clinic trial readout
support broader human sequenc
limit diagnost oncolog
increas trend sourc sequenc
lab limit instrument demand
risk achiev price
clinic trial ahead timelin
updat clinic guidelin support
broad use oncolog applic
reacceler research channel
meaning competit emerg
medium term
exhibit nih disburs appear slow recent
guidanc
guidanc
lower
flat revenue
flat revenue
exhibit chang forecast
rev
rev
rev
rev
rev
rev
extend ra panel vectibix
phase analysi servic whole-genom
compani data morgan stanley research
strive trial women
ccga expand patient
philip data health system
bgi buy pacbio sequel system long read
us gr launch gr row
launch genestudio sequenc new assay
valuat risk
exhibit valuat ev/sal elev ile rel
exhibit valuat price-to-earnings ile rel
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
thomson reuter morgan stanley research
price target base yield estim view base
uptak clinic applic remain concentr academ
commun hospit refin eas use new softwar
sampl prepar system on-going regulatori approv guidelin
inclus anticip emerg research market growth remain
limit competit emerg medium term
valu driver includ physician group support clinic guidelin evolut
broader adopt system includ public expert consortia
clinic trial group fda insur support includ regulatori approv
standard test posit reimburs polici expand interest research
support tailor genom guid therapi innov sampl
prepar softwar support adopt user smaller clinic hospit
risk price target includ clinic trial guidelin timelin hospit
govern budget constraint new competit
